United Kingdom

People: Cidara Therapeutics Inc (CDTX.OQ)

CDTX.OQ on NASDAQ Stock Exchange Global Market

6:12pm BST
Change (% chg)

$0.09 (+5.62%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Sandison, Taylor 

Dr. Taylor Sandison, M.D., M.P.H., has been appointed as Chief Medical Officer of the Company. Dr. Sandison has been with Cidara since October 2015. Prior to joining the company, he served as senior medical director at Cubist Pharmaceuticals, Inc. from July 2014 to January 2015 and then, following Merck's acquisition of Cubist, as senior medical director at Merck from February to October 2015. Dr. Sandison has also held positions at Trius Therapeutics and Novartis Diagnostics, and served as a member of the faculty in the Department of Medicine at both Stanford University and the University of Washington. He received B.S. and B.A. degrees from Dartmouth College, and M.D. and M.P.H. degrees from the University of Washington. He completed residency training at the University of Colorado and fellowship training at the University of Washington. Dr. Sandison holds board certifications in Infectious Diseases and Internal Medicine.

Basic Compensation

Total Annual Compensation, USD 338,000
Restricted Stock Award, USD 278,000
Long-Term Incentive Plans, USD --
All Other, USD 383,266
Fiscal Year Total, USD 999,266

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --